Press releases

12 releases

8/27/2026 Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. ↗ (opens in a new tab) 8/26/2026 JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis ↗ (opens in a new tab) 8/6/2026 Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) ↗ (opens in a new tab) 4/2/2026 Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) ↗ (opens in a new tab) 3/28/2026 New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis ↗ (opens in a new tab)

In the news

11 articles

8/27/2026 FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults ↗ (opens in a new tab) 12/4/2025 Developing Targeted Therapies for a Rare Autoimmune Disease ↗ (opens in a new tab) 11/20/2025 First-In-Class Therapies For Severe Autoimmune Disorders ↗ (opens in a new tab) 10/15/2024 Biotech Formed by Pfizer, Roivant Eyes Treatment for Rare Diseases ↗ (opens in a new tab) 9/6/2024 Progress, Potential, and Possibilities Podcast: Novel Therapies for Severe Autoimmune Diseases ↗ (opens in a new tab)